The different and often opposite data concerning IL-17A levels and the relationship with pro-fibrotic cytokines and fibrotic processes observed in several tissues of SSc patients, would suggest that IL-17A modulates fibrogenesis rather than exerts a net pro-fibrotic or anti-fibrotic effect. The gene discussed is IL17A; the disease is systemic sclerosis.